Recombinant serotype 5 adenovirus (Ad5) vectors lacking E1 expression induce robust immune responses against encoded transgenes in pre-clinical models, but have muted responses in human trials because of widespread pre-existing anti-adenovirus immunity. Attempts to circumvent Ad5-specific immunity by using alternative serotypes or modifying capsid components have not yielded profound clinical improvement. To address this issue, we explored a novel alternative strategy, specifically reducing the expression of structural Ad5 genes by creating E1 and E2b deleted recombinant Ad5 vectors. Our data show that [E1À, E2bÀ]vectors retaining the Ad5 serotype are potent immunogens in pre-clinical models despite the presence of significant Ad5specific immunity, in contrast to [E1À] vectors. These pre-clinical studies with E1 and E2b-deleted recombinant Ad5 vectors suggest that anti-Ad immunity will no longer be a limiting factor, and that clinical trials to evaluate their performance are warranted.
Introduction
Despite promising results in murine models, cancer vaccines have not been proven clinically effective in human clinical trials. 1 Many cancer vaccines target nonmutated 'self' antigens expressed aberrantly by tumor cells, such as carcinoembryonic antigen (CEA). Where as CEA expression in adults is normally limited to low levels in the gastrointestinal epithelium, 2 CEA is highly expressed in the majority of colorectal cancers and in many breast, lung and pancreas cancers. 2, 3 Immune responses are weak to tumor antigens such as CEA in humans because of strong immunologic tolerance to these proteins. As a consequence, a minimal requirement for cancer vaccines that target non-mutated self antigens is a need to overcome immune tolerance.
Recombinant viral vector vaccines have been shown to overcome tolerance in a variety of animal models and in clinical studies. We and others have earlier tested recombinant fowlpox vectors in clinical trials and observed the induction of detectable anti-CEA immunity. 4 Nonetheless, we have seen limited boosting effects with repeated immunizations, suggesting that anti-fowlpox immune responses were limiting the expression and subsequent immune response to CEA. Even using vaccination strategies to avoid neutralizing antibodies, such as ex vivo infection of dendritic cells (DC), did not lead to boosting. 4 Consequently, we sought to develop alternative viral vectors to use alone or in heterologous vector prime-boost strategies to enhance CEA-specific immunity.
Recombinant adenovirus (Ad) vectors are the most widely used viral vectors in clinical gene therapy applications including vaccines. [5] [6] [7] [8] The commonly used Ad5 serotype has an extensive and accepted safety profile, as well as allowing for maximal induction of transgenespecific adaptive immune responses. [9] [10] [11] The prototypic Ad vectors are E1 deleted and considered to be replicationdefective but have been shown to allow for limited genome replication and expression of toxic Ad-gene products. As a result, recombinant Ad5 vaccines have limited efficacy in the presence of widely prevalent neutralizing antibodies and T-cell responses to Ad5. This anti-vector immunity limits the infection of host antigen-presenting cells (APCs) in vivo and consequently also limits immune responses to the vector-encoded vaccine antigen(s).
We have a significant interest in the modification of Ad-based vectors to optimize them for use as cancer vaccines. We retained the Ad5-based vaccine platform and made genomic modifications to determine whether we could improve its efficacy, and particularly whether these modifications can evade the effects of pre-existing anti-Ad5 immunity. We constructed two new Ad5 vectors (referred to as replicating and non-replicating) expressing CEA and compared them with the prototypical Ad5[E1À] vector used in most clinical studies. Critically, we found that the non-replicating Ad5 vector deleted for the E1, E2b, E3 genes was strikingly superior to the Ad5 E1deleted vector and was capable of generating CEAspecific T-cell responses in mice with pre-existing Ad5 immunity that were equal to responses in naive mice. These results suggest that pre-existing Ad5 immunity is no longer a limiting factor to the use of Ad5-based vaccines, and that future clinical trials to evaluate their performance are warranted.
Materials and methods

Reagents
Flourescent-conjugated antibodies for flow cytometry assay were purchased from BD Bioscience (San Jose, CA). HLA-A*0201-restricted CMVpp65(495-503) peptide (NLVPMVATV) and MART-1(26-35) peptide (EAAGI GILTV) were purchased from Research Genetics (Huntsville, AL). 15mer peptide mix of CEA, cytomegalovirus (CMV)pp65 and HIV were purchased from BD Bioscience. Peptide-MHC tetramers for HLA-A*0201 restricted-CMVpp65(495-503) peptides and control tetramer were purchased from Beckman Coulter (San Diego, CA).
Adenovirus vector preparation
Construction of a first-generation [E1À] Ad vector containing a human CEA or human CMVpp65 antigen under the control of human CMV promoter/enhancer elements was carried out as described earlier. 12 Briefly, the CEA gene or CMVpp65 gene under the expression control of the 576-bp human CMV promoter/enhancer was subcloned into a shuttle plasmid and used to generate Ad5[E1À]CEA vector or Ad5[E1À]CMV vector. The modified adenoviral vector, Ad [E1À, E2b-], was constructed as described earlier. 13 This vector has multiple depletion for early region 1 (E1) and E2b regions (DNA polymerase and pTP genes) and was engineered to express the identical human CMV promoter/enhancer-transgene cassette as utilized for the Ad[E1À]CEA or Ad[E1À]CMV vector. Complementing C-7 cell lines were used to support the growth and production of high titers of these vectors, and cesium chloride double banding was carried out to purify the vectors, as reported earlier. 14 The replicating Ad5[E1 þ ] vectors, which only have the deletion of E3 gene, were also made for comparison purposes, as theoretically they would produce higher levels of transgene expression.
Human peripheral blood samples
Peripheral blood samples from healthy human volunteers were obtained under Duke IRB-approved protocols.
Infection of human dendritic cells with Ad5-CEA vectors
Dendritic cells were cultured from peripheral blood mononuclear cells (PBMC) of healthy human volunteers in AIM-V medium (Invitrogen, Carlsbad, CA) supplemented with recombinant human GM-CSF (800 IU ml -1 ) and IL-4 (25 ng ml -1 , R&D Systems, Minneapolis, MN) for 7 days. DC were harvested and 3 Â 10 6 cells in 1 ml of AIM-V medium were infected with Ad5-CEA or Ad5-CMV vectors at indicated multiplicity of infection (MOI of 0, 500, 5000, 10 000, 20 000, 40 000, 80 000) numbers for 1 h in single wells of six-well plates. Then, 4 ml of AIM-V medium was added to each well and incubation was continued for 2 days. For the temporal analysis of CEA expression, DC were infected with Ad5-CEA at MOI 20 000 and incubated for 6-96 h.
To analyze the efficacy of transgene expression, DC were harvested and stained with fluorescein isothiocyanate (FITC)-conjugated anti-CD86, PE-conjugated anti-CEA, PerCP-conjugated anti-HLA-DR, and APC-conjugated anti-CD14. CD14-negative HLA-DR-positive DC were analyzed for their CEA expression. To analyze the effect of Ad-vector infection on DC viability, DC were also stained and labeled with Annexin-V-biotin (Beckman Coulter, Marseille, France) and then stained with APC-conjugated streptavidin together with 7-AAD (Beckman Coulter), FITC-conjugated anti-CEA and PE-conjugated anti-HLA-DR. Large HLA-DR-positive cells were analyzed for 7-AAD/Annexin labeling.
To assess the effect of Ad-vector infection on DC maturation status, DC were stained with PerCP-conjugated anti-HLA-DR, APC-conjugated anti-CD14 and PE-conjugated antibodies against the following molecules: CD40, CD54, CD80, CD83, CD86, CCR5 and CCR7. Antibodies for flow cytometry were purchased from BD Bioscience otherwise noted.
NK-mediated cell killing of Ad-vector-infected DC
Seven-day-cultured DC from a normal donor were infected with Ad5-CEA vectors at MOI 20 000 and incubated for 2 days. NK cells were harvested from the same donor's PBMC using NK cell isolation kit (Miltenyi Biotec) and incubated overnight with IL-2 (1000 U ml -1 ). Harvested DC were incubated with autologous NK cells for 6 h. Supernatants were used for lactate dehydrogenase (LDH) cytotoxicity assay (CytoTox 96) according to the manufacturer's instruction (Promega, Madison, MI).
Cytotoxic T lymphocyte activation by Ad-infected DC
Seven-day-cultured DC from normal donor (HLA-A2 þ , CMV þ ) were infected with Ad vectors encoding CMVpp65 or CEA antigens for 2 h and incubated for 2 days. 1 Â 10 4 DC transduced with the vectors (MOI 20 000) were used as stimulators and 1 Â 10 4 or 5 Â 10 4 of CMVpp65 CTL line was used as responder cells. A CMVpp65 polypeptide mix of 15mers overlapping by 11 representing the CMVpp65 protein was used as a positive E1, E2b and E3-deleted Ad5 vector vaccine response T Osada et al control, and a HIV gag polypeptide mix was used as a control for the CMV mix. After 20 h of incubation, IFN-g ELISPOT assay (Mabtech Inc., Cincinnati, OH) was performed according to the manufacturer's instruction. After 40 h of incubation, supernatants were harvested from each well and IFN-g ELISA was carried out.
In vitro cytotoxic T lymphocytes expansion with Ad5-CMV-infected DC Seven-day-cultured DC from a normal donor (HLA-A2 þ , CMV þ ) were infected with Ad5-CMV at MOI 20 000 and incubated for 2 days. DC were harvested from plates and mixed with autologous peripheral blood lymphocytes (PBLs) at 10:1 (PBL/DC) ratio. On day 3 and 7, IL-2 (300 IU ml -1 ) was added to the culture and cells were harvested for tetramer assay on day 10. Cells were stained with FITC-conjugated anti-CD3, PerCPconjugated anti-CD8, APC-conjugated anti-CD4, CD14, and CD19, and PE-conjugated CMVpp65 tetramer or control tetramer. CD3 þ CD4ÀCD14ÀCD19À lymphocytes were gated and the percentages of tetramer-positive cells in CD8 T cells were analyzed.
Mice C57BL/6 mice were purchased from Jackson Labs (Bar Harbor, ME) and all work was conducted in accordance with Duke IACUC-approved protocols.
Assessment of vector immunogenicity in vivo
In order to compare the capacity of Ad vectors with different constructs to establish CEA-specific immunity and to induce production of anti-adenovirus antibody in vivo, mice were vaccinated once through footpad injection of Ad5-CMV vectors or Ad5-CEA vectors (2.6 Â 10 10 particles per mouse). Fourteen days later, mice were euthanized, and splenocytes and sera were collected for analysis. IFN-g ELISPOT assay was carried out to examine the CEA-specific T-cell responses and ELISA for CEA-specific antibodies was carried out, as described below.
Modeling pre-existing anti-Ad immunity in vivo To create a model of pre-existing anti-Ad immunity, mice were injected with 5 Â 10 10 particles of a Ad5[E1 þ ]CMV vector through the footpad either on day 0, 14, and 28, or only on day 28, or received control saline injections (Adnaive mice). Blood was drawn on day 42 in order to quantify mouse anti-adenovirus antibody through ELI-SA, as described below. Mice were injected with 2.6 Â 10 10 particles of the respective Ad5-CEA vectors on days 42, 49 and 56. Two weeks after the last vaccination, mice were euthanized, and splenocytes and serum were harvested. IFN-g ELISPOT assay was carried out to examine the CEA-specific T-cell responses and ELISA for CEAspecific antibodies was carried out, as described below.
ELISPOT analysis to detect antigen-specific T-cell responses from mouse splenocytes Mouse IFN-g ELISPOT assay (Mabtech Inc.) was carried out according to the manufacturer's instruction. Spleno-cytes (500 000 cells per well) were added to the well, and CMVpp65 peptide mix or CEA peptide mix (2.6 mg ml -1 : BD Bioscience, San Jose, CA) was used as a stimulating antigen. Peptide mixes consist of 15mers overlapping by 11 amino acids and cover the entire protein sequence. HIV peptide mix (BD Bioscience) was used as a negative control, and a mixture of paramethoxyamphetamine (PMA) (50 ng ml -1 ) and ionomycin (1 mg ml -1 ) was used as a positive control of the assay.
ELISA for anti-adenovirus antibodies
Microtiter plates (Immulon 4BX, Dynex Technologies, Chantilly, VA) were coated with 1 Â 10 9 total particles of Ad5[E1 þ ]CEA virus in bicarbonate buffer (200 mM NaHCO 3 , 81mM Na 2 CO 3 , pH 9.5) overnight. After blocking for an hour with a solution of 1% bovine serum albumin (BSA), 5% sucrose, 0.05% NaN 3 in phosphate buffered saline (PBS) and mouse serum (diluted 1:40 to 1:320 000) were added to the wells and incubated for 2 h at 37 1C, followed by incubation with 100 ml of a 1:2500 dilution of sheep alkaline phosphatase-conjugated antimouse IgG antibody (Jackson Immunoresearch Laboratories, West Grove, PA) for 1 h at 37 1C. Plates were washed three times and 50 ml per well of the p-nitrophenyl phosphate (pNPP) substrate solution (5 mg ml -1 , pNPP, Sigma, St Louis, MO) was added to each well. The reaction was stopped by adding 50 ml per well of NaOH solution. Absorbance was measured at 405 nm.
ELISA for anti-transgene antibodies
Mouse sera were collected and frozen at À80 1C until use. Microtiter plates (Immulon 4BX, Dynex Technologies, Chantilly, VA) were coated with CEA peptide mix or CMVpp65 peptide mix (BD Bioscience) at a concentration of 2.6 mg ml -1 . Plates were incubated at 4 1C overnight, washed with PBS and blocked with 1% BSA in PBS for 1 h. Thawed sera were diluted with the titration of 1:40 to 1:320 000 with 1% BSA in PBS, added to each well and incubated for 2 h. Sera from Ad-naive mice (salineinjected mice) were used as a negative control. Incubation with anti-mouse IgG antibody and color development was carried out as described above. 
Statistical analyses
An unpaired Student's t-test was used to analyze the statistical difference.
Results
As Ad replication may significantly affect the efficacy of Ad-based vaccines, we developed Ad5-based vectors expressing CEA under control of an identical CMV enhancer/promoter element, but differing only in the deletion of critical Ad genes. Specifically, we generated a prototypic CEA-expressing Ad vector that had deletions of the E1 and E3 region Ad genes (Ad5[E1À, E3À]CEA; henceforth referred to as Ad5[E1À]CEA), but also two novel Ad vaccines. The first was a non-replicating vector deleted not only for the Ad-E1 and -E3 genes, but also for the Ad-E2b genes, (Ad5[E1À, E2bÀ, E3À]CEA; henceforth referred to as Ad5[E1À, E2bÀ]CEA). This gene transfer platform has been shown earlier to allow for decreased toxicity and improved persistence of transgene expression in immunecompetent animals. 15 The second was an Ad vector that retains the E1 genes but is deleted for the E3 gene (Ad5[E1 þ , E3À]CEA; henceforth referred to as Ad5[E1 þ ]CEA). This design allows for Ad-genome replication, which we hypothesized might provide improved transgene expression and possibly enhanced vaccine responses.
Before testing the performance of these vectors in the setting of Ad-specific immunity, we set out to characterize these vectors using critical in vitro and in vivo assays of vaccine efficacy.
Infection of human DC and assessment of vector toxicity Adenoviral vector vaccines achieve much of their effects either by the infection of APC or by the production of antigen that is subsequently processed and presented by APC. Therefore we studied the antigen expression of CEA in human DC in vitro after co-culture with the three vectors.
Human monocyte-derived DC were infected and their CEA expression was analyzed (Figure 1a Figure 1b ). This is perhaps not surprising given each vector's inherent replicative activity. When the toxicity of Ad5-vector infection was analyzed using Annexin-V labeling as a measure of apoptotic cell death of DC (Figure 1c ), the non-replicative Ad5[E1À, E2bÀ]CEA vector always yielded the best viability of DC, while particularly at higher MOI the Ad5[E1 þ ]CEA led to significant apoptotic cell death.
Temporal kinetics of CEA expression by human dendritic cells after Ad5-vector infection The kinetics of CEA expression and apoptosis in the Adinfected human DC was analyzed at MOI 20 000, because this MOI produced a similar infection rate with each vector (Figure 1a ). Interestingly, these three vectors showed very similar levels of CEA expression over time (Figure 1d ), suggesting that while the total amount of CEA protein being made within the DC differed ( Figure 1b ) the expression kinetics of CEA did not differ. However, the Ad5[E1 þ ]CEA vector induced a higher rate of apoptotic cell death in DC after the 48-h time point (Figure 1e ).
Does Ad-vector infection induce maturation of human DC?
The maturation status of DC is an important determinant of the quality of the resulting immune response, whether ex vivo Ad5-modified DC are used as a vaccine, or an Ad vaccine is injected and infects endogenous DC in vivo.
Consequently, expression of maturation markers on infected DC was analyzed by flow cytometry (Figure 2) . The CEA expression level and MFI showed comparable levels of infection for each vector in this experiment. CD40, CD86 and CCR7 expression was moderately enhanced by Ad-vector infection, with all three Ad vectors yielding similar increases in MFI compared with mock-infected DC. CD83 expression was not altered by Ad5-CEA infection.
Are Ad-vector-modified DC targets for NK cell-mediated lysis?
The design of the three Ad vectors suggested that they would lead to different levels of Ad genome-derived protein expression in infected APC in vivo, which might render them susceptible to innate immunity mediated by NK cells. We evaluated NK cell killing of Ad5-CEAinfected DC using an in vitro autologous human cell culture system consisting of Ad5-CEA-infected DC and autologous NK cells. The similar levels of CEA expression on infected DC confirmed equivalent Ad infectivity for the three different Ad5-CEA vectors (data not shown). Despite this, the Ad5[E1 þ ]CEA vector-infected DC were significantly more susceptible to NK-mediated cytotoxicity (Figure 3 ). Importantly, DC infected with the Ad5[E1À]CEA and Ad5[E1À, E2bÀ]CEA vectors were not susceptible to NK-mediated lysis, with the levels of cytotoxicity similar to that of mock-infected DC.
Ad5-transduced DC induce antigen-specific cellular responses in vitro
The induction of antigen-specific cytotoxic T cells will be a major component of a successful cancer vaccine strategy. Therefore, we evaluated the antigen-presenting capacity of Ad5-infected DC using a CMVpp65-specific CTL line (clone 3H1) 
Ad5-transduced DC induce expansion of CMV-specific CTLs in vitro
Although the earlier experiment showed the capacity of Ad-infected DC to process and present peptide to a T-cell clone, we hypothesized that genome replication differences invoked by the different vaccine constructs could limit the effectiveness of the infected DC to expand antigen-specific T cells. PBL from an HLA-A2 þ /CMVsero-positive donor were cultured with Ad5-CMV-transduced autologous DC, and the expansion of CMVpp65specific CTL was analyzed (Figure 4b ). The largest expansion of CMVpp65-specific T-cells was induced by the Ad5[E1À]CMV and Ad5[E1À, E2bÀ]CMV-transduced DC. These results corresponded well to the results from the earlier assay evaluating antigen-presenting capacity (Figure 4a ), and again indirectly suggest that Ad-genome replication can negatively affect the efficacy of Ad vaccines.
Modeling anti-Ad5 immunity in mice As many people have been naturally infected by and recovered from wild-type adenovirus, vaccination in humans commonly occurs in the setting of pre-existing Ad5 immunity, which limits the effectiveness of Ad5 vaccines clinically. [16] [17] [18] Once our in vitro studies showed the characteristics of the three Ad5-based vector constructs, we sought to examine each vector as a vaccine in vivo, both in naive animals, and critically, in the context of pre-existing immunity to Ad5.
To model Ad5 immunity in mice, we exposed naive mice to either a single dose or three doses of a replicationcompetent Ad5[E1 þ , E3þ ] (Ad5[RC]) expressing a heterologous transgene encoded in the E4 region. The Ad5[RC] vector was chosen because it represented most closely the wild-type Ad5 that humans are exposed to. As shown in Figure 5a , a single dose of this Ad5[RC] vector elicited anti-Ad antibody endpoint titers of 1:5000, while three doses increased this to 1:20 000. The cellular immune responses to each of the vectors after three doses of the Ad[RC] vector was also determined. As we had predicted, T-cell responses were greatest against the Ad5[E1 þ ] vector. We noted an attenuated T-cell response to the prototypic Ad5[E1À] vector. Importantly, we found a dramatic and highly significant reduction in T-cell response against our novel Ad5[E1À, E2bÀ] vector. In fact, there was no proliferation of Ad5-specific T cells in response to the Ad5[E1À, E2bÀ]CEA (Figure 5b ).
Induction of anti-CEA T-cell responses with the Ad5[E1À, E2bÀ]CEA vector is not diminished in mice with pre-existing anti-Ad5 immunity
We prepared either Ad5-naive or Ad5-immune mice, the latter receiving one or three doses of Ad5[RC] . These mice were then vaccinated with three doses of the Ad5[E1À, E2bÀ]CEA, Ad5[E1À]CEA or Ad5[E1 þ ]CEA vectors, and levels of CEA-specific CTL responses were measured ( Figure 6 ). The Ad5[E1 þ ]CEA vector showed the strongest CEA-specific T-cell response in naive mice, but the induction of CEA-specific T-cell responses was dramatically less effective when this vaccine construct was utilized in mice that had pre-existing anti-Ad5 immunity. The reductions in magnitude of the CEA-specific response were 36 and 48%, respectively, for one and three prior Ad5[RC] injections. Similarly, the Ad5[E1À]CEA vector showed a dramatic reduction in the level of CEA-specific T cells in mice that received one and three prior doses of the Ad5[RC] vector. Responses were again diminished by 37-46% in the Ad5-immune mice, as compared with the naive mice. In contrast, there was little effect of preexisting anti-Ad immunity on CEA-specific T-cell responses when the Ad5[E1À, E2bÀ]CEA vector was used . Even three earlier doses of the Ad5[RC] vector associated with 1:20 000 anti-Ad5 antibody titers only reduced the magnitude of Ad5[E1À, E2bÀ]CEA-induced CEA-specific T cells by 10% and there was no decrease in mice that had received a single Ad5[RC] exposure. These results were highly significant. Thus, the use of Ad5[E1À, E2bÀ]CEA vaccine retains the full potential of immune induction by Ad5 vaccines, but overcomes anti-Ad5specific immune responses that significantly limit other Ad5-based vaccine constructs.
Discussion
Unlike gene therapy applications where vector persistence requires immunologically 'quiet' vectors, vaccines benefit from some degree of vector-induced inflammation that The performance of the three vectors was compared ex vivo using human DC. Notably, the Ad-infected DC were more potent than peptide-loaded DC in inducing T-cell responses in vitro, as has been reported earlier . [19] [20] [21] These studies further showed that all three vectors gave similar infectivity and temporal dynamics of transgene expression. There were differences, however, with the replicating Ad5[E1 þ ]CEA vector perhaps not surprisingly showing greater evidence of DC toxicity, eliciting less maturation of DC, and clearly making Ad5[E1 þ ]CEA-infected DC targets for NK-mediated innate immunity. These findings directly correlated with our findings that the Ad5[E1À] and Ad5[E1À, E2bÀ] vectors were superior to the Ad5[E1 þ ] vector in their capacity to induce and expand antigen specific T-cell responses. The results suggest that increased replication of an Ad vector may result in diminished efficacy of the overall platform. There were also indications that the [E1À, E2bÀ] performed better than the [E1À] platform, likely because of its inherent inability to replicate its genome because of the deletion of the Ad-E2b genes. These indications were verified when the Ad5[E1À, E2bÀ]CEA vaccine platform was stringently tested in vivo.
The role of anti-Ad5 immunity and neutralizing antibodies has been recognized as a major obstacle for Ad-based vaccine strategies using serotype 5, as well as for some other prevalent Ad serotypes. We pre-immunized mice with single or triple doses of 10 11 Ad5replicating virus, to produce high levels of pre-existing anti-Ad5 immunity, analogous to the approach of Roberts et al. 22 In order to maximize anti-Ad5 humoral and cellular immunity, we used the footpad route of administration, which results in greater levels of immunogenicity than those with sub-cutaneous or intra-muscular injection (unpublished observation). Importantly, challenge of Ad5 pre-immune mice with the Ad5[E1À, E2bÀ]CEA vector did not induce T-cell proliferative responses, suggesting that the deletion of the E2b gene results in a loss of expression of major epitopes recognized by the anti-Ad5 T cells.
More dramatically, there was little blunting of the immune response to CEA elicited by the Ad5[E1À, E2bÀ]CEA vector when comparing the magnitude of the response in naive mice with the magnitude in mice with high levels of pre-existing anti-Ad5 immunity. In contrast, the Ad5[E1 þ ]CEA and Ad5[E1À]CEA vectors were markedly less effective when confronted with preexisting anti-Ad5 immunity, with CEA-specific immune responses diminished by 48 and 46%, respectively. Importantly, similar data have also been obtained in non-human primates (Dr Frank Jones, personal communication; manuscript in preparation). These data not only show the improved efficacy of the Ad5[E1À, E2bÀ]CEA vector platform in Ad5-immune mice, but also show that antibody responses to the Ad5 capsid are not primarily responsible for the lack of efficacy of Ad5-based vaccines in the context of pre-existing Ad5 immunity. Other mechanisms targeting Ad genes may be primarily responsible. As an example, one major focus of the anti-Ad adaptive immune response is to the hexon proteins. 16, 17, 23, 24 We hypothesize that APC infected by the Ad5[E1À, E2bÀ]CEA vector may be less susceptible to attenuation by pre-existing anti-Ad immunity because, subsequent to infection, the Ad5[E1À, E2bÀ] vector produces significantly lower levels of multiple Ad-late proteins, proteins that include highly immunogenic proteins such as hexon. We reason that DC infected by the Ad5[E1À, E2bÀ]CEA vector in vivo are not cleared as rapidly (possibly in a NK-cell-dependent mechanism), allowing more time for immune responses to the CEA transgene to develop.
Why should the additional deletion of the E2b gene have such a profound effect on Ad5-based vaccines in the face of pre-existing anti-Ad5 immunity? We have earlier reported microarray studies comparing the Ad5[E1À] and Ad5[E1À, E2bÀ] vectors in vivo. Livers from Ad-infected mice showed similar gene expression profiles at 6 h postinfection (HPI) for the Ad5[E1À] and Ad5[E1À, E2bÀ] vectors, but at 72 h post-infection there was markedly lower expression of inflammatory genes with the Ad5[E1À, E2bÀ] vector (published online at NCBI Gene Omnibus Express (GEO) (http://www.ncbi.nlm.nih.gov/ geo/) accession numbers GSE3729 and GSE4339). 25 Whereas the similar early gene inductions suggest that these events may be primarily capsid driven, the reduced inflammatory response at 72 h post-infection probably results from the significantly diminished Ad-gene expression with the Ad5[E1À,E2b-] vector, as deletion of E2b prevents expression of late gene products as compared with Ad5[E1À] vectors. 14, [26] [27] [28] The Ad5[E1À, E2bÀ] vectors have also been shown to have reduced hepatic toxicity when administered i.v. and better persistence in vivo, also suggesting a less robust immune response to the Ad5[E1À, E2bÀ] vector itself. 15 Although all of these studies involved intravascular administration of vector rather than the s.c. (footpad) route used in our vaccine studies, they do suggest that the Ad5[E1À, E2bÀ] vector has different characteristics than mute anti-Ad immune responses, generating a more potent CEA-specific immune response in Ad5 pre-immune animals.
Alternate strategies to negate the effect of pre-existing anti-Ad5 immunity have included the vectorization of alternate serotype Ads, although several recent reports confirm that the use of alternative serotype Ads can directly lead to the altered production of important chemokines and cytokines, altered gene dysregulation, as well as significantly different biodistribution and tissue toxicities in animal models and when tested in human DC, relative to Ad5 vectors. 29, 30 The use of hexon-chimeric adenoviruses created by replacing the Ad5 hexon-hypervariable regions with those from other Ad serotypes may also help avoid neutralizing antibody responses to the native Ad5 capsid. 22, 29, 31, 32 However, there is also evidence that hexons from other sub-groups tend to reduce vector infectivity, alter antigen-specific antibody isotype responses and skew the Th1-Th2 balance, 11, 32 and that whereas Ad5-mediated transduction of certain antigens can induce humoral responses, other serotypes, when vectorized, fail to do so. 33 We believe our studies show that the Ad5[E1À, E2bÀ] vector can yield stronger immune responses in Ad5 preimmune individuals than standard Ad5[E1À] vectors. We conclude that the Ad5[E1À, E2bÀ] vector platform has great potential for circumventing pre-existing anti-Ad5 immunity and warrants testing in human clinical trials.
